Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The supplements are made using only vegetarian-sourced ingredients
The approval is backed by data showing deep, durable responses and manageable tolerability
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
Subscribe To Our Newsletter & Stay Updated
